鹽酸小檗堿作用機制 - Medchemexpress - MCE中國

1、Product Data SheetBerberine chlorideCat. No.: HY-18258CAS No.: 633-65-8分式: CHClNO分量: 371.81作靶點: Topoisomerase; Autophagy; Bacterial; Reactive Oxygen Species作通路: Cell Cycle/DNA Damage; Autophagy; Anti-infection; Immunology/Inflammation;Metabolic Enzyme/Protease; NF-B儲存式: Store at room temperature* In

2、 solvent : -80C, 6 months; -20C, 1 month (Store at room temperature)溶解性數(shù)據(jù)體外實驗 DMSO : 12.5 mg/mL (33.62 mM; Need ultrasonic)H2O : 1 mg/mL (2.69 mM; Need ultrasonic)SolventMass1 mg 5 mg 10 mgConcentration制備儲備液1 mM 2.6895 mL 13.4477 mL 26.8955 mL5 mM 0.5379 mL 2.6895 mL 5.3791 mL10 mM 0.2690 mL 1.3448

3、mL 2.6895 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存式和期限：-80C, 6 months; -20C, 1 month。-80C 儲存時，請在 6 個內(nèi)使，-20C 儲存時，請在 1 個內(nèi)使。體內(nèi)實驗請根據(jù)您的實驗動物和給藥式選擇適當?shù)娜芙獍?。以下溶解案都請先按?In Vitro 式配制澄清的儲備液，再依次添加助溶劑：為保證實驗結果的可靠性，澄 的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的作液，建議您現(xiàn)現(xiàn)配，當天使； 以下溶劑前顯的百分 指該溶劑在您配制終溶液中的體積占；如在配制過程中出現(xiàn)沉淀、析

4、出現(xiàn)象，可以通過加熱和/或超聲的式助溶1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 1.25 mg/mL (3.36 mM); Clear solution此案可獲得 1.25 mg/mL (3.36 mM，飽和度未知) 的澄清溶液。以 1 mL 作液為例，取 100 L 12.5 mg/mL 的澄 DMSO 儲備液加到 400 L PEG300 中，混合均勻；向上述體系中加50 L Tween-80，混合均勻；然后繼續(xù)加 450 L 理鹽定容 1 mL。2. 請依序添加每種溶劑： 10% DMSO 90

5、% (20% SBE-CD in saline)Solubility: 1.25 mg/mL (3.36 mM); Clear solution此案可獲得 1.25 mg/mL (3.36 mM，飽和度未知) 的澄清溶液。Page 1 of 2 www.MedChemE以 1 mL 作液為例，取 100 L 12.5 mg/mL 的澄均勻。DMSO 儲備液加到 900 L 20% 的 SBE-CD 理鹽溶液中，混合BIOLOGICAL ACTIVITY物活性 Berberine chloride 從中草藥 連中分離出來的種物堿，常作抗素。Berberine chloride 誘導活性氧 (RO

6、S) 成并抑制 DNA 拓撲異構酶 (topoisomerase)。抗腫瘤特性1。IC & Target ROS1DNA topoisomerase1體外研究Berberine (1.25-160 M; 72 hours) has potential inhibitory effects on the proliferation of four colorectal carcinoma celllines LoVo, HCT116, SW480, and HT-291.Berberine (1.25-160 M; 24-72 hours) induces a time- and dose-de

7、pendent inhibition of LoVo cell growth1.LoVo cells are exposure to Berberine (10-80 M) for 24 h. Cell cycle analysis of 40 M Berberine-treated LoVo cells byflow cytometry shows accumulation of cells in the G2/M phase1.Berberine (10-80 M) suppresses cyclin B1, cdc2 and cdc25c protein expression after

8、 24 h, especially at the dose of80.0 M1.Cell Proliferation Assay1Cell Line: Four colorectal carcinoma cell lines LoVo, HCT116, SW480, and HT-29Concentration: 1.25, 2.5, 5, 10, 20, 40, 80, and 160 MIncubation Time: 72 hoursResult: Inhibited the proliferation of four cell lines. The IC50 ranged from 4

9、0.84.1 M (LoVo)to 98.62.9 M (HCT116).Cell Proliferation Assay1Cell Line: Colorectal carcinoma cell lines LoVoConcentration: 1.25, 2.5, 5, 10, 20, 40, 80, and 160 MIncubation Time: 24, 48, 72 hoursResult: Induced a time- and dose-dependent inhibition of cell growth. By 72 h, 160.0 Minduced 71.11.9 %

10、growth inhibitions in LoVo cells.Cell Cycle Analysis1Cell Line: LoVo cellsConcentration: 0, 10, 20, 40, or 80 MIncubation Time: 24 hoursResult: Exposure to 40.0 M induced G2/M-phase cell cycle arrest, an increase in the G2/M-phase population and a progressive decline in the G1 population.Western Blo

11、t Analysis1Page 2 of 3 www.MedChemECell Line: LoVo cellsConcentration: 10, 20, 40, or 80 MIncubation Time: 24 hoursResult: Suppressed cyclin B1, cdc2 and cdc25c protein expression.體內(nèi)研究 Berberine (10, 30, or 50 mg/kg/day; gastrointestinal gavage; for 10 consecutive days) inhibits the growth of humanc

12、olorectal adenocarcinoma in vivo. Berberine at doses of 30 and 50 mg/kg/day taken by gastrointestinal gavage shows inhibitory rates of 33.1% and 45.3% on the human colorectal adenocarcinoma xenograft growth in nude mice1.Animal Model: 5-week-old BALB/c nu/nu mice with human colorectal adenocarcinoma

13、 LoVoxenografts1Dosage: 10, 30, or 50 mg/kg/dayAdministration: Gastrointestinal gavage; for 10 consecutive daysResult: Showed inhibitory rates of 33.1 % and 45.3 % at doses of 30 and 50 mg/kg/day.戶使本產(chǎn)品發(fā)表的科研獻 Exp Cell Res. 2020 May 3:112054.See more customer validations on HYPERLINK www.MedChemE www.MedChemEREFERENCES1. Cai Y, et al. Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. J Nat Med. 2014 Jan;68(1):53-62.McePdfHeightCaution